 |
|
|
|
|
| 2008 |
| November 03, 2008 |
Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD |
| October 23, 2008 |
Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis |
| June 25, 2008 |
Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients |
| June 16, 2008 |
GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections |
| Mar 4, 2008 |
Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis |
| 2007 |
| Sept 17, 2007 |
Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer |
| July 18, 2007 |
Mpex Pharmaceuticals Initiates Multi-dose Clinical Trial in the U.S. with MP-376 in Patients with Cystic Fibrosis |
| May 22, 2007 |
Mpex Pharmaceuticals Names Daniel D. Burgess as Chief Executive Officer |
| 2006 |
| May 1, 2006 |
Mpex Pharmaceuticals Names Dana Krzyston to the Newly-Created Position of Vice President of Finance and Operations |
| 2005 |
| Oct 31, 2005 |
Mpex Pharmaceuticals Names Michael Dudley to Newly-Created Position of Vice President, Drug Development |
| Aug 9, 2005 |
Mpex Pharmaceuticals Closes $32 Million Series B Financing |
|
|
|
|
|
|
